I have made the above post after research,first of all...second I myself am biology student..so who could understand chemicals and their effects on various biological processes more then us?
I dont know that what kind of discussion is going on here as I haven't seen 10 page long debate...but I am seeing that a sort if misunderstanding is observed among people here.
Keeping all the siyasi conversation away.. Let me again elucidate that Factor 8 is an essential protein found in our body.It's deficiency causes haemophelia.
When we are injured.. this protein triggers a series of reactions as a result of it's stimulus ..a series of reaction is initiated to clot and heal our wounds.
Now what it has to do with cancer and hemophilia? well this medicine is used to stop bleeding
IIt doesn't triggers coagulation, it's also emetegenic, the side effects are a lot for any anti-cancerous drugs, i wonder after injecting this they would be able to keep a cool head.
All chemotherapy agents, produce nausea, vomiting,headaches etc.There is no way around this.
Doxorubicin drug information | DrugsUpdate India
Do you know what you write? it contains Doxorubicin
Doxorubicin trade name Adriamycin; also known as hydroxydaunorubicin) is a drug used in cancer chemotherapy. It is an anthracycline antibiotic, closely related to the natural product daunomycin, and like all anthracyclines it intercalates DNA. It is commonly used in the treatment of a wide range of cancers, including hematological malignancies, many types of carcinoma, and soft tissue sarcomas.
The drug is administered in the form of hydrochloride salt intravenously. It may be sold under the brand names Adriamycin PFS, Adriamycin RDF, or Rubex.It is photosensitive and it is often covered by an aluminum bag to prevent light from affecting it.
Pharmacokinetics
Doxorubicin is a cytotoxic anthracycline antibiotic. The cytotoxic action results from its binding to DNA and inhibition of nucleic acid synthesis. Doxorubicin has been shown to produce regression in a variety of disseminated malignancies.
Absorption: Rapidly cleared from the blood after IV admin.
Distribution: Distributed into tissues including lungs, liver, heart, spleen and kidneys (IV); crosses the placenta; enters breast milk.
Metabolism: Hepatic; rapidly converted to doxorubicinol.
Excretion: Bile (as unchanged drug); 12 min, 3.3 hr, 30 hr (mean elimination half-lives).
Doxorubicin Adverse Reactions / Doxorubicin Side Effects
Leucopenia, thrombocytopenia, nausea, vomiting, diarrhoea. Rarely facial flushing, rash, alopecia. Blurred vision, headache, seizures, paraesthesia, confusion, malaise, lethargy, skin pigmentation.
Potentially Fatal: Bone marrow suppression, cardiotoxicity.
Precautions
General
Doxorubicin is not an anti-microbial agent. Doxorubicin is emetigenic. Antiemetics may reduce nausea and vomiting; prophylactic use of antiemetics should be considered before administration of Doxorubicin, particularly when given in conjunction with other emetigenic drugs.
Overdosage:
Acute overdosage may increase the toxic effects of mucositis, leukopenia and thrombocytopenia. Treatment includes hospitalisation of the severely myelosuppressed patient, antimicrobials, platelet transfusions and symptomatic treatment of mucositis. Use of haemopoietic growth factor (G-CSF, GM-CSF) may be considered. Cumulative dosage increases risk of cardiomyopathy and resultant congestive heart failure which may be managed with digitalis preparations, diuretics, and after load reducers such as ACE inhibitors.
Special Precautions
Elderly, children, hepatic impairment. Monitor blood counts and ECG.
Other Drug Interactions
Doxorubicin interacts with a number of other drugs e.g. antibiotics (aminoglycosides), steroids, aminophylline and propranolol.
Potentially Fatal: Cholestasis induced by mercaptopurine may be potentiated by concurrent administration of the drug. Toxicity may be increased if streptozocin is given concurrently.
Dosage
Intravenous
AIDS-related Kaposi's sarcoma
Adult: As pegylated liposome: 20 mg/m2 BSA infused over 30 min once every 2-3 wk.
Hepatic impairment: Moderate impairment (serum-bilirubin: 12-30 mcg/mL): Half the normal dose; severe impairment (serum-bilirubin >30 mcg/mL): Quarter of the usual dose.
Intravenous
Ovarian carcinoma
Adult: As pegylated liposome: 50 mg/m2 BSA infused over 1 hr once every 4 wk.
Hepatic impairment: Moderate impairment (serum-bilirubin: 12-30 mcg/mL): Half the normal dose; severe impairment (serum-bilirubin >30 mcg/mL): Quarter of the usual dose.
Intravenous
Metastatic breast cancer
Adult: 60-75 mg/m2 BSA once every 3 wk in combination with cyclophosphamide given as an infusion over 1 hr diluted in 0.9% sodium chloride or 5% glucose.
Hepatic impairment: Moderate impairment (serum-bilirubin: 12-30 mcg/mL): Half the normal dose; severe impairment (serum-bilirubin >30 mcg/mL): Quarter of the usual dose. Irrigation
Local malignant neoplasms in the bladder
Adult: 50 ml of a 1 mg/ml solution instilled into the bladder for 1 hr once a mth.
Hepatic impairment: Moderate impairment (serum-bilirubin: 12-30 mcg/mL): Half the normal dose; severe impairment (serum-bilirubin >30 mcg/mL): Quarter of the usual dose.
